Oncologist Epidemiologist,Cancer Genetics | passionate about cancer prevention, improving outcomes for survivors, mentoring & DEI. Love a laugh.Tweets my own
Great mentors expand your capacity while also sharpening your focus.
They help you to see all of the things that you’re capable of doing while also helping you to choose which of those things are worth pursuing.
I am unbelievably humbled and honored to be selected among this incredible group of physician-scientists. Thank you to @DamonRunyon for this opportunity, and to my mentors, Cindy Sears and Drew Pardoll. @HopkinsMedicine@hopkinskimmel
Proud daughter alert! My mother's art on the August cover of @DiabetesCareADA in celebration of her 80th birthday.
About the Artist: Nancy Selvin https://t.co/aLfwjTciv4
@chanders4@StevenKahn11
Take that, imposter syndrome!
Wasn't going to post, but need to celebrate the victories in this line of work, right? Can't believe this finally happened after the trauma of covid/young kids in a soft money position.
Shout out to my MPIs Suzanne Bell and @Dr_DylanJackson!
Study shows that patients with #thyroidcancer who received radioactive iodine have a higher risk of second primary #cancer that rises with cumulative radioactive iodine dose. #RAI#SPM#Research#thycsm
Read more here: https://t.co/iLaHxUC1A8
Just thanks as I've ended as the @jhubiostat Chair. Dear department friends-so many of you being with me at my farewell meant so much; same to JHU friends & family. Feeling truly privileged as I paddle into the sunset (photo authentic!) of chair life relishing my & dept's future!
48% of employees who fear telling colleagues about their cancer are also worried
about losing their job.
Support ending the stigma and uncertainty for those with a cancer diagnosis and pledge #workingwithcancer.👇
https://t.co/WPsVAML0q7
#cancerawareness#makethepledge
The Brown Lab is moving to KUMC!
This fantastic opportunity will allow me to work with the @KUcancercenter and the @KUDiabetesInst to build research efforts to decipher the etiology of #obesity-related #cancers and identify new risk reduction strategies.
The Nat’l Academies @nasem wants to understand how to promote equity for STEMM professionals w/caregiving responsibilities outside of work, especially caregivers of color. Check out https://t.co/jk1JLKdotU if you’d be willing to be interviewed (via Zoom)!
We have created a database of funding opportunities for early-career faculty/researchers in oncology/cancer research.
For each of the 86 opportunities, we provide a description, link, $ amount, deadline, and eligibility criteria.
Download for free here: https://t.co/RGXGrdp2uf
A few advocate spots remain for GRASP discussions of work presented at #ASCO23 to take place on June 14 & 15. These are virtual, small-group discussions between scientists & patients, with six time options. Sign up for an account & register for a session! https://t.co/5ynzaZaYiA
HER2 Testing: ASCO-CAP Guideline Update. Imp and helpful commentary @awolff - at that low level, IHC is really sensitive to subtle analytic factors. A slide sitting unstained for a week or so might change a 1+ to a 0 result. #bcsm https://t.co/925VfAKOQ3
Researchers from @DanaFarber Cancer Institute have found a way to detect an increased cancer risk associated with BRCA1 and BRCA2 mutations without genetic sequencing, opening the door to more affordable, accessible tests.
https://t.co/EGYd4ubvGV
It has been a week of deep emotion as family has taken precedence over all. A roller coaster, while the valley remains private, I’ll share this peak- my beautiful daughter, my sun and moon and brightest star, graduates summa cum laude and heads to college in the fall 💕
Honored to be Assistant Vice Chair for Women’s Careers in Academic Medicine for @JohnsHopkinsDOM working to advance women promotion, advancement and equity. Excited to work with Drs. Risha Irvin and Helene Hedian in our shared initiatives @Hopkins_GIM@HopkinsMedicine
#ASCO23 Dr. @BarYaelMD shows that if we biopsy enough times, we’ll get a HER2-low (83% after 3 bx & 100% after 5 bx in this dataset). Is this just sampling or true evolution? We don’t know (or if the answer even matters. Include pts w/ marker-neg tumors in early drug dev.) #bcsm